Second quarter Net Product Sales of $36.0 million , which increased from $31.8 million for the same period in 2023 ZYNRELEF ® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024 ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act") SAN DIEGO , Aug.
6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX ) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024 , and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success.
We are improving the financial efficiency of the business by growing revenues, improving margins, and reducing expenses. Regarding ZYNRELEF, we continue to expand our partnership with CrossLink and progress our regulatory activities in anticipation of a fourth quarter launch of the VAN," said Craig Collard , Chief Executive Officer of Heron. Business Highlights The range for adjusted operating expenses guidance for 2024 is being narrowed from $108.
0 million to $116.0 million to a revised $107.0 million to $111.
0 million . Additionally, the range for adjusted EBITDA guidance is being narrowed from $(22.0) million to $3.
0 million to a revised $(10) million to $3.0 million . The ZYNRELEF VAN PDUFA goal date is set for September 23, 2024 .
The VAN is designed to allow for easier and more efficient.